FDA Approves First Human Clinical Trial of Mitragynine as OUD Treatment

Why it matters

The FDA's clearance of the first randomized, double-blind human trial of mitragynine marks a pivotal shift in how the federal government views kratom as a potential therapeutic — not just a substance to regulate or ban. For millions of Americans with opioid use disorder, this opens a credible treatment pipeline.

The big picture

Kratom has long existed in a regulatory gray zone — informally used by many for opioid withdrawal management while simultaneously facing federal scrutiny and proposed bans. The FDA and DEA had been moving to schedule 7-hydroxymitragynine (7-OH), kratom's more potent derivative, as a Schedule I substance. The approval of an Investigational New Drug (IND) application for purified mitragynine (formulated as MG001) signals a deliberate bifurcation of federal policy: targeting synthetic, concentrated 7-OH products while potentially clearing a path for plant-derived mitragynine as a legitimate medicine.

Key findings

• The FDA approved a NIDA-sponsored IND for MG001, a purified mitragynine formulation, to study its safety and tolerability in humans.
• The study is the first randomized, double-blind, placebo-controlled trial of mitragynine in humans, enrolling approximately 32 volunteers.
• Researchers from NIDA and the University of Florida developed the purified mitragynine formulation used in the trial.
• The study is part of the federal HEAL (Helping to End Addiction Long-term) Initiative.
• NIDA Director Nora Volkow called FDA clearance a 'major step toward expanding treatment options for the millions of Americans struggling with opioid use disorder.'
• President Trump separately expressed support for 'natural 7-OH,' suggesting broader administration interest in kratom-derived therapies.

What they say

"This research study is the first time the new medication MG001 is being tested in people," states a NIDA summary. "The purpose of this study is to understand how safe MG001 is, how well it is tolerated, and how the body processes it."

Bottom line

The FDA's green-light for the first human mitragynine trial represents the clearest federal signal yet that kratom's primary alkaloid may have a legitimate future as a prescription treatment for opioid use disorder.